{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964520,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T00:00:00Z","timestamp":1541808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD Haar Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00296-018-4180-4","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T01:08:51Z","timestamp":1541812131000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany"],"prefix":"10.1007","volume":"39","author":[{"given":"Klaus","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Wassenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bohl-B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias H.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,10]]},"reference":[{"key":"4180_CR1","unstructured":"Weldring T, Smith SM (2013) Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 6: 61\u201368"},{"key":"4180_CR2","unstructured":"European Medicines Agency Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products; EMEA\/CHMP\/EWP\/139391\/2004 London, 27 July 2005. Internet: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500003637&mid=WC0b01ac058009a3dc\n                    \n                  . Accessed on 28 May 2018"},{"key":"4180_CR3","unstructured":"Food and Drug Administration Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, USA. December (2009) Internet: \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\n                    \n                  . Accessed on 28 May 2018"},{"key":"4180_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1136\/annrheumdis-2011-201201","volume":"71","author":"SJ Bartlett","year":"2012","unstructured":"Bartlett SJ, Hewlett S, Bingham CO, et al (2012) Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 71:1855\u20131860","journal-title":"Ann Rheum Dis"},{"key":"4180_CR5","first-page":"350","volume":"31","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Combe B, Burmester G (2013) Understanding the patient perspective\u2014results of the rheumatoid arthritis: insights, strategies and expectations (RAISE) patient needs survey. Clin Exp Rheumatol 31:350\u2013357","journal-title":"Clin Exp Rheumatol"},{"key":"4180_CR6","first-page":"51","volume":"5","author":"J Wollenhaupt","year":"2013","unstructured":"Wollenhaupt J, Ehlebracht-Koenig I, Groenewegen A, Fricke D (2013) Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany. Open Access Rheumatol 5:51\u201367","journal-title":"Open Access Rheumatol"},{"key":"4180_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00393-009-0569-5","volume":"69","author":"W Graninger","year":"2010","unstructured":"Graninger W, Gross WL, Raspe H (2010) Quality of life in rheumatic diseases. Z Rheumatol 69:197","journal-title":"Z Rheumatol"},{"key":"4180_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509","journal-title":"Ann Rheum Dis"},{"key":"4180_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA (2010) Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 70:121\u2013145","journal-title":"Drugs"},{"key":"4180_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.clinthera.2010.09.003","volume":"32","author":"EG Boyce","year":"2010","unstructured":"Boyce EG, Halilovic J, Stan-Ugbene O (2010) Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther 32:1681\u20131703","journal-title":"Clin Ther"},{"key":"4180_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L et al (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68:789\u2013796","journal-title":"Ann Rheum Dis"},{"key":"4180_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986","journal-title":"Arthritis Rheum"},{"key":"4180_CR13","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58:3402\u20133412","journal-title":"Arthritis Rheum"},{"key":"4180_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","volume":"73","author":"J Braun","year":"2014","unstructured":"Braun J, Baraliakos X, Hermann KG et al (2014) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73:1107\u20131113","journal-title":"Ann Rheum Dis"},{"key":"4180_CR15","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E et al (2016) Five-year safety data from 5 clinical trials of subcutaneous Golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 43:2120\u20132130","journal-title":"J Rheumatol"},{"key":"4180_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3899\/jrheum.150712","volume":"43","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Genovese MC, Hall S et al (2016) Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol 43:298\u2013306","journal-title":"J Rheumatol"},{"key":"4180_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2015","unstructured":"Emery P, Fleischmann RM, Strusberg I et al (2015) Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial. Arthritis Care Res (Hoboken)\u00a068:744\u2013752","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4180_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, Braun J, Inman RD et al (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74:757\u2013761","journal-title":"Ann Rheum Dis"},{"key":"4180_CR19","first-page":"263","volume":"31","author":"JE Frampton","year":"2017","unstructured":"Frampton JE (2017) Golimumab: a review in inflammatory arthritis. Bio Drugs 31:263\u2013274","journal-title":"Bio Drugs"},{"key":"4180_CR20","doi-asserted-by":"publisher","first-page":"e021082","DOI":"10.1136\/bmjopen-2017-021082","volume":"0","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Burmester G, Wassenberg S, Bohl-B\u00fchler M, Thomas M (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis under real-life clinical conditions: GO-NICE study in Germany. BMJ Open 0:e021082. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2017-021082","journal-title":"BMJ Open"},{"key":"4180_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00393-013-1264-0","volume":"73","author":"J Ruof","year":"2014","unstructured":"Ruof J, Iking-Konert C, Simianer S, Burmester GR (2014) [Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany: real-life clinical practice data]. Zeitschrift Rheumatol 73:65\u201373","journal-title":"Zeitschrift Rheumatol"},{"key":"4180_CR22","unstructured":"European Agency for the Evaluation of Medicinal Products (EMA) Simponi (Golimumab) Summary of Product Characteristics (SmPC). Latest renewal of authorisation 19 June 2014. Internet: \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed on 28 May 2018"},{"key":"4180_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM (2005) Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 6:124\u2013130","journal-title":"Eur J Health Econ"},{"key":"4180_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s003930050030","volume":"56","author":"J Lautenschlager","year":"1997","unstructured":"Lautenschlager J, Mau W, Kohlmann T et al (1997) Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire. Z Rheumatol 56:144\u2013155","journal-title":"Z Rheumatol"},{"key":"4180_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, Peterman A, Slavin M (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528\u2013538","journal-title":"Cancer"},{"key":"4180_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, Gladman DD (2007) Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 66:936\u2013939","journal-title":"Ann Rheum Dis"},{"key":"4180_CR27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"4180_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.013","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A (2018) General population norms for the functional assessment of chronic illness therapy (FACIT)-Fatigue Scale. Value Health. \n                    https:\/\/doi.org\/10.1016\/j.jval.2018.03.013\n                    \n                   (in press)","journal-title":"Value Health"},{"key":"4180_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210\u2013221","journal-title":"Lancet"},{"key":"4180_CR30","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272\u20132283","journal-title":"Arthritis Rheum"},{"key":"4180_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"4180_CR32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D Heijde van der","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J et al (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41:1095\u20131103","journal-title":"J Rheumatol"},{"key":"4180_CR33","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s10067-017-3757-8","volume":"36","author":"M Gaubitz","year":"2017","unstructured":"Gaubitz M, G\u00f6ttl K-H, Behmer O, Lippe R, Meng T, L\u00f6schmann P-A (2017) Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. Clin Rheumatol 36:1989\u20131996","journal-title":"Clin Rheumatol"},{"key":"4180_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11926-017-0649-5","volume":"19","author":"P Katz","year":"2017","unstructured":"Katz P (2017) Fatigue in rheumatoid arthritis. Curr Rheumatol Rep 19:25","journal-title":"Curr Rheumatol Rep"},{"key":"4180_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/annrheumdis-2016-209835","volume":"76","author":"LH Tuyl van","year":"2017","unstructured":"van Tuyl LH, Sadlonova M, Hewlett S et al (2017) The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Annals Rheum Dis 76:855\u2013861","journal-title":"Annals Rheum Dis"},{"issue":"11","key":"4180_CR36","first-page":"S64-85","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(11):S64-85","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4180_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10067-011-1887-y","volume":"31","author":"RCJ Campbell","year":"2012","unstructured":"Campbell RCJ, Batley M, Hammond A, Ibrahim F, Kingsley G, Scott DL (2012) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 31:717\u2013722","journal-title":"Clin Rheumatol"},{"key":"4180_CR38","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3899\/jrheum.121200","volume":"40","author":"V Strand","year":"2013","unstructured":"Strand V, Schett G, Hu C, Stevens RM (2013) Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol 40:1158\u20131165","journal-title":"J Rheumatol"},{"key":"4180_CR39","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL et al (2016) Effect of Secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68:2901\u20132910","journal-title":"Arthritis Rheumatol"},{"key":"4180_CR40","doi-asserted-by":"publisher","first-page":"e012281","DOI":"10.1136\/bmjopen-2016-012281","volume":"6","author":"D Kyte","year":"2016","unstructured":"Kyte D, Ives J, Draper H, Calvert M (2016) Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management. BMJ Open 6:e012281","journal-title":"BMJ Open"},{"key":"4180_CR41","doi-asserted-by":"publisher","first-page":"e0144658","DOI":"10.1371\/journal.pone.0144658","volume":"11","author":"D Kyte","year":"2016","unstructured":"Kyte D, Ives J, Draper H, Calvert M (2016) Management of patient-reported outcome (PRO) alerts in clinical trials: a cross sectional survey. PLoS One 11:e0144658","journal-title":"PLoS One"},{"key":"4180_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA registry. Rheumatol Ther 4:489\u2013502","journal-title":"Rheumatol Ther"},{"key":"4180_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jech.2003.008466","volume":"58","author":"M Delgado-Rodriguez","year":"2004","unstructured":"Delgado-Rodriguez M, Llorca J (2004) Bias. J Epidemiol Community Health 58:635\u2013641","journal-title":"J Epidemiol Community Health"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4180-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T19:30:55Z","timestamp":1573327855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4180-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4180"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4180-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,10]]},"assertion":[{"value":"9 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and standards of Good Clinical Practice. The primary ethics approval was obtained from the Ethics Committee of the Ludwig-Maximilian University in Munich on 17 February 2010 (number 008\u201310). All patients provided written informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available as they concern a proprietary product and sharing is not explicitly covered by patient consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The sponsor MSD Sharp & Dohme GmbH funded this observational study and had a role in the design of the study and critical revision of the manuscript, in close collaboration with the scientific advisors of this study (co-authors). The authors confirm that there was on influence of the funding on the results and the conclusion.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}}]}}